Novel Technology and Emerging Studies

Phase I, open-label, first-in-human study to evaluate the safety and feasibility of personalized tissue-engineered vein grafts in patients with chronic venous insufficiency.

Presenter(s)

• AG

  Andrés García León, MD

  Hospital Universitario Virgen de Valme
  Sevilla, Andalucia, Spain

Co-Author(s)

• JL

  José Patricio Linares Palomino, MD

  Hospital Universitario Virgen de Valme
  Sevilla, Andalucia, Spain
• MR

  Manuel Rodríguez Pinero, MD

  Hospital Universitario Virgen de Valme
  Sevilla, Andalucia, Spain
• AR

  Antonio Romera Villegas, MD

  Hospital Universitario Virgen de Valme
  Sevilla, Andalucia, Spain
• LC

  Laura Calsina, MD

  Hospital Universitario Virgen de Valme
  Sevilla, Andalucia, Spain
• AM

  Ana Moreno, MD

  Hospital Universitario Virgen de Valme
  Sevilla, Andalucia, Spain
• LS

  Luis Miguel Salmerón Febres, MD

  Hospital Universitario Virgen de Valme
  Sevilla, Andalucia, Spain
• PB

  Petter Björquist, PhD

  CEO
  VERIGRAFT AB
  Göteborg, Vastra Gotaland, Sweden
• RS

  Raimund Strehl, PhD

  VERIGRAFT AB
  Göteborg, Vastra Gotaland, Sweden
• JH

  Jan Holgersson, MD PhD

  VERIGRAFT AB
  Göteborg, Vastra Gotaland, Sweden